LeonaBio
Share
We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration.
We are dedicated to the development of novel therapeutics for diseases with high unmet needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patient’s lives. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is
01/09/2026
Today marks an important milestone for our company.
Athira Pharma is now LeonaBio, Inc., reflecting a transformative new chapter following our acquisition of rights to lasofoxifene, a Phase 3 program in metastatic breast cancer. Along with our new name, our Nasdaq ticker will change to LONA, effective January 12, 2026.
We remain dedicated to advancing innovative therapies for patients with serious diseases and high unmet medical need.
Read the full announcement: https://investors.athira.com/static-files/5a0c261e-d22b-4af9-87c7-bc15bda7315b
Today marks an important milestone for our company.
Athira Pharma is now LeonaBio, Inc., reflecting a transformative new chapter following our acquisition of rights to lasofoxifene, a Phase 3 program in metastatic breast cancer. Along with our new name, our Nasdaq ticker will change to LONA, effective January 12, 2026.
We remain dedicated to advancing innovative therapies for patients with serious diseases and high unmet medical need.
Read the full announcement here: https://investors.athira.com/static-files/5a0c261e-d22b-4af9-87c7-bc15bda7315b
This Friday, join us at the Alzheimer's Association, Orange County Chapter Research Advances event bringing together caregivers, patients, families, researchers, and healthcare professionals to learn about the latest in and dementia research.
Thank you to the Alzheimer’s Association for hosting this informative event to drive and educate on global research initiatives - we’re honored to be a presenting sponsor supporting this cause.
Register at no cost: https://alzassociationoc.wixstudio.io/research-advances
08/20/2024
Our Phase 2/3 LIFT-AD Study is evaluating the safety and efficacy of for the treatment of mild-to-moderate Alzheimer’s disease. Hear more on our company progress from CEO Mark Litton, Ph.D. as we approach our topline data readout of the clinical trial.
Learn more about : https://bit.ly/3zmY3Ip
08/14/2024
The mild-to-moderate stage of disease is characterized by heightened cognitive and functional decline leading to loss of patient independence. Despite this being the most distressing stage for patients and loved ones, there are currently no approved therapies to slow neurodegeneration for this specific population.
Fosgonimeton has the potential to address the mild-to-moderate stage of by providing neuroprotection and neuronal restoration, potentially reversing neurodegenerative symptoms. Stay tuned as we report topline data from our Phase 2/3 LIFT-AD clinical trial evaluating in AD in September.
Learn more: https://bit.ly/48NcRwO
08/12/2024
With multiple key data readouts expected, the space is poised for significant developments in the second half of 2024. In her recent BioSpace article, Heather McKenzie summarizes the highly anticipated neurological disease data readouts, including our LIFT-AD Phase 2/3 topline results of as a potential differentiated Alzheimer’s treatment.
Access the full article:
5 Neuro Data Readouts to Watch in the Second Half of 2024 After a busy first half of 2024, several companies are expecting key data readouts in the neuropsychiatric and neurodegenerative disease spaces during the next six months.
08/07/2024
That’s a wrap on ! Thank you for joining our discussion of ’s neuroprotective preclinical activity in models.
See you next year!
The mild-to-moderate stage of Alzheimer’s disease can be the most distressing and detrimental stage for patients, which is why disease-modifying treatments are pivotal to effectively tackle and potentially reverse neurodegeneration progression at this stage.
Hear from Dr. Anton Porsteinsson on the unmet need for new treatments to reduce patient burden below.
Listen to the full webinar on Alzheimer’s and the LIFT-AD clinical trial: https://bit.ly/3zrFW3O
07/16/2024
What’s at stake for us? Developing therapies to counteract progression of neurodegenerative diseases— our vision and mission.
President and CEO Mark Litton, Ph.D., sat down with Life Science Leader's Wayne Koberstein to highlight our approach, his experience leading the Athira team, our pipeline progress throughout the years and what’s to come.
https://bit.ly/4cO95W4
Companies To Watch: Athira Pharma Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.
The last patient has completed dosing in our Phase 2/3 LIFT-AD clinical trial evaluating in mild-to-moderate disease, with topline results anticipated by end of Q3 2024.
Read the full announcement: https://investors.athira.com/news-releases/news-release-details/athira-pharma-announces-last-patient-completed-lift-ad-clinical
Click here to claim your Sponsored Listing.
Category
Contact the business
Website
Address
18706 North Creek Parkway, Suite 104
Seattle, WA
98011